Phacilitate Leaders World

Speakers

Loading
Wolfgang  Knirsch

Wolfgang Knirsch

CEO, Vita 34 AG

Dr. Wolfgang Knirsch is a Member of the Management Board of Vita 34 since June 2016.

Following successful completion of his doctorate in Inorganic Chemistry at RWTH Aachen, Dr. Knirsch moved from institutional research to the pharmaceutical industry in 1992.

Dr. Knirsch began this career step traditionally in Sales and Marketing at Hoechst AG. Later he was responsible for the product management of internationally relevant ethical preparations of the successor company Aventis Pharma GmbH. After moving to Merck KGaA he was responsible, inter alia, for new business as well as later for the national marketing of the most important drug sector of the company.

In 2005 Dr. Knirsch took on responsibility for strategic and operative marketing at Biotest AG, a specialist in clinical immunology, hematology, intensive and emergency medicine. Following the successful restructuring and reorientation of this area, he moved within that company to their international business in 2011. In his capacity as Vice President International Business, he developed a strategically relevant area of responsibility of several hundred million dollars successfully with global sales partners.

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK